ENTX

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

Entera Bio shares slip as Q2 loss comes in wider than expected

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs